Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the underlying mechanism of MS. Preliminary imaging data have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, which are often difficult to detect with conventional imaging.
This milestone is significant because it brings the company closer to validating a non-invasive method to monitor myelin damage in real time. Currently, clinicians rely on MRI scans that measure inflammation and tissue damage indirectly, but they do not directly visualize demyelination. A validated PET tracer could provide a more precise tool for diagnosing MS, tracking disease progression, and evaluating the efficacy of potential treatments. For patients, this could mean earlier detection of lesion activity and more personalized treatment strategies.
Quantum BioPharma believes the imaging technique could enhance the development of MS therapies, including its own investigational candidate, Lucid-MS. Lucid-MS is a patented new chemical entity designed to prevent and reverse myelin degradation. In March 2026, the company submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 trial of Lucid-MS. The imaging study’s findings could provide critical biomarkers to support the drug’s clinical development and regulatory approval.
The study is a collaboration with Massachusetts General Hospital, a leading research institution. The company has not disclosed the total target enrollment or the expected completion date. However, reaching the midpoint suggests steady progress. Investors and the medical community will be watching for final results, which could influence the trajectory of MS diagnostics and therapeutics.
Beyond MS, Quantum BioPharma is building a portfolio of assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its subsidiary Lucid Psycheceuticals Inc., the company is focused on Lucid-MS. Additionally, Quantum holds a 19.84% stake in Unbuzzd Wellness Inc., which markets an over-the-counter product called UNBUZZD(TM) for alcohol effects, with royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity.
For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/4IZ0y.
